Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Gilead Sciences Q4 earnings fall short of estimates

Published 02/06/2024, 04:57 PM
Updated 02/06/2024, 04:57 PM
©  Reuters -- Gilead Sciences reported Tuesday fourth-quarter earnings that missed analyst estimates as sales of its HIV treatment rose less than expected. 

Gilead Sciences Inc (NASDAQ:GILD) fell more than 2% in afterhours trading following the results.

The California-based company reported adjusted earnings per share of $1.72 on revenue of $7.1 billion, compared with estimates of $1.76 on revenue of $7.1B.

Sales of Gilead's HIV treatment Biktarvy, which drives a significant portion of product sales, rose 6.5% to $3.11B, slightly missing estimates of $3.21. 

Looking ahead to 2024, the company said it expects adjusted diluted earnings of between $6.85 and $7.25 per share on revenue of $27.1B and $27.5B, compared with forecasts of $7.19 a share on revenue of $27.63B.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.